Treatments for Dry Age-related Macular Degeneration: Therapeutic Avenues, Clinical Trials and Future Directions

Overview

Journal Br J Ophthalmol

Specialty Ophthalmology

Date 2021 Mar 20

PMID 33741584

Citations 75

Authors

Thales Antonio Cabral de Guimaraes

Malena Daich Varela

Michalis Georgiou

Michel Michaelides

Affiliations

Soon will be listed here.

Abstract

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. The identification of the central role of vascular endothelial growth factor (VEGF) in the pathogenesis of neovascular AMD and the introduction of anti-VEGF agents as gold-standard treatment, have drastically changed its prognosis-something yet to be seen in dry AMD. Several therapeutic avenues with a wide variability of targets are currently being investigated in dry AMD. The approaches being investigated to reduce the rate of disease progression include, (1) drugs with antioxidative properties, (2) inhibitors of the complement cascade, (3) neuroprotective agents, (4) visual cycle inhibitors, (5) gene therapy and (6) cell-based therapies. A number of early phase clinical trials have provided promising results, with many more ongoing and anticipated in the near future. In this review, we aim to provide an update of the interventional trials to date and future prospects for the treatment of dry AMD.

Citing Articles

Co-delivery of antioxidants and siRNA-VEGF: promising treatment for age-related macular degeneration.

Dias M, Cruz-Cazarim E, Pittella F, Baiao A, Pacheco A, Sarmento B Drug Deliv Transl Res. 2025; .

PMID: 39751765 DOI: 10.1007/s13346-024-01772-x.

Systemic inflammatory regulators and age-related macular degeneration: a bidirectional Mendelian randomization study.

Liu X, Cao Y, Wang Y, Kang L, Zhang G, Zhang J Front Genet. 2024; 15:1391999.

PMID: 39734575 PMC: 11671502. DOI: 10.3389/fgene.2024.1391999.

Causal association between metabolites and age-related macular degeneration: a bidirectional two-sample mendelian randomization study.

Liu Z, Zhang H, Sun X, Liu J Hereditas. 2024; 161(1):51.

PMID: 39707561 PMC: 11662531. DOI: 10.1186/s41065-024-00356-6.

Inherited Retinal Degenerations and Non-Neovascular Age-Related Macular Degeneration: Progress and Unmet Needs.

Duncan J, Bowman A, Laster A, Gelfman C, Birch D, Boye S Transl Vis Sci Technol. 2024; 13(12):28.

PMID: 39688851 PMC: 11654773. DOI: 10.1167/tvst.13.12.28.

ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation.

Ehlers J, Hu A, Boyer D, Cousins S, Waheed N, Rosenfeld P Ophthalmol Sci. 2024; 5(1):100628.

PMID: 39605874 PMC: 11599447. DOI: 10.1016/j.xops.2024.100628.

References

Cashman S, Ramo K, Kumar-Singh R . A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration. PLoS One. 2011; 6(4):e19078. PMC: 3084256. DOI: 10.1371/journal.pone.0019078. View

Phillips M, Walker T, Choi H, Faulkner A, Kim M, Sidney S . Tauroursodeoxycholic acid preservation of photoreceptor structure and function in the rd10 mouse through postnatal day 30. Invest Ophthalmol Vis Sci. 2008; 49(5):2148-55. PMC: 2626193. DOI: 10.1167/iovs.07-1012. View

Mullins R, Dewald A, Streb L, Wang K, Kuehn M, Stone E . Elevated membrane attack complex in human choroid with high risk complement factor H genotypes. Exp Eye Res. 2011; 93(4):565-7. PMC: 3206185. DOI: 10.1016/j.exer.2011.06.015. View

Kauper K, McGovern C, Sherman S, Heatherton P, Rapoza R, Stabila P . Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. Invest Ophthalmol Vis Sci. 2012; 53(12):7484-91. DOI: 10.1167/iovs.12-9970. View

Kim S, Park S, Byun S, Park K, Suh H . Incremental economic burden associated with exudative age-related macular degeneration: a population-based study. BMC Health Serv Res. 2019; 19(1):828. PMC: 6852978. DOI: 10.1186/s12913-019-4666-0. View

Bird A, Bressler N, Bressler S, Chisholm I, Coscas G, Davis M . An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol. 1995; 39(5):367-74. DOI: 10.1016/s0039-6257(05)80092-x. View

Parsons C, Ruitenberg M, Freitag C, Sroka-Saidi K, Russ H, Rammes G . MRZ-99030 - A novel modulator of Aβ aggregation: I - Mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD). Neuropharmacology. 2015; 92:158-69. DOI: 10.1016/j.neuropharm.2014.12.038. View

Klein R, Davis M, Magli Y, Segal P, Klein B, Hubbard L . The Wisconsin age-related maculopathy grading system. Ophthalmology. 1991; 98(7):1128-34. DOI: 10.1016/s0161-6420(91)32186-9. View

Ding X, Patel M, Chan C . Molecular pathology of age-related macular degeneration. Prog Retin Eye Res. 2008; 28(1):1-18. PMC: 2715284. DOI: 10.1016/j.preteyeres.2008.10.001. View

10.

Evans J, Lawrenson J . Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev. 2017; 7:CD000254. PMC: 6483465. DOI: 10.1002/14651858.CD000254.pub4. View

11.

Ferris 3rd F, Wilkinson C, Bird A, Chakravarthy U, Chew E, Csaky K . Clinical classification of age-related macular degeneration. Ophthalmology. 2013; 120(4):844-51. PMC: 11551519. DOI: 10.1016/j.ophtha.2012.10.036. View

12.

Rosenfeld P, Dugel P, Holz F, Heier J, Pearlman J, Novack R . Emixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Clinical Trial. Ophthalmology. 2018; 125(10):1556-1567. DOI: 10.1016/j.ophtha.2018.03.059. View

13.

Datta S, Cano M, Ebrahimi K, Wang L, Handa J . The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD. Prog Retin Eye Res. 2017; 60:201-218. PMC: 5600827. DOI: 10.1016/j.preteyeres.2017.03.002. View

14.

Lafuente M, Villegas-Perez M, Sobrado-Calvo P, Garcia-Aviles A, de Imperial J, Vidal-Sanz M . Neuroprotective effects of alpha(2)-selective adrenergic agonists against ischemia-induced retinal ganglion cell death. Invest Ophthalmol Vis Sci. 2001; 42(9):2074-84. View

15.

Kumar-Singh R . The role of complement membrane attack complex in dry and wet AMD - From hypothesis to clinical trials. Exp Eye Res. 2019; 184:266-277. DOI: 10.1016/j.exer.2019.05.006. View

16.

Whitmore S, Sohn E, Chirco K, Drack A, Stone E, Tucker B . Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy. Prog Retin Eye Res. 2014; 45:1-29. PMC: 4339497. DOI: 10.1016/j.preteyeres.2014.11.005. View

17.

Lachmann P . The story of complement factor I. Immunobiology. 2019; 224(4):511-517. DOI: 10.1016/j.imbio.2019.05.003. View

18.

Cruess A, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery A . Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study. Pharmacoeconomics. 2007; 26(1):57-73. DOI: 10.2165/00019053-200826010-00006. View

19.

Ma L, Kaufman Y, Zhang J, Washington I . C20-D3-vitamin A slows lipofuscin accumulation and electrophysiological retinal degeneration in a mouse model of Stargardt disease. J Biol Chem. 2010; 286(10):7966-7974. PMC: 3048683. DOI: 10.1074/jbc.M110.178657. View

20.

Merin S, Obolensky A, Farber M, Chowers I . A pilot study of topical treatment with an alpha2-agonist in patients with retinal dystrophies. J Ocul Pharmacol Ther. 2008; 24(1):80-6. DOI: 10.1089/jop.2007.0022. View